Ventyx Biosciences (VTYX) Outlook Strengthened by Cost Optimization and Positive Clinical Data
I'm PortAI, I can summarize articles.
Canaccord Genuity increased its price target for Ventyx Biosciences (NASDAQ:VTYX) from $14 to $16, maintaining a Buy rating after the company's Q3 results. The stock is noted as one of the hottest SMID-cap stocks in 2025, with the outlook strengthened by cost optimization and positive clinical data.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments